Six recurring decisions in drug development

Drug development is often shown as a sequence: preclinical research, Phase 1, Phase 2, Phase 3, submission, and launch. The decisions surrounding an asset are less orderly.

A program can have encouraging clinical results but require more capital than its sponsor can justify. A marketing application can be assembled while an unresolved manufacturing issue threatens its prospects in review. A diligence finding can change both a buyer's interest and the work required after a deal closes.

The following six questions are a practical management framework, not formal regulatory gates. Their relevance and timing vary by product and stage. What matters is whether new evidence changes an earlier answer.

1. Should we advance?

A positive study result does not answer this question by itself. Teams must weigh the strength and uncertainty of the efficacy signal, dose and exposure-response, target engagement, safety findings, translational evidence, and the feasibility of the next study.

The decision is whether the available evidence justifies the next commitment of patient exposure, time, and capital. It may support advancing as planned, advancing with a different dose or study design, gathering more evidence first, or stopping. We worked through one version of that choice in detail in what decision intelligence looks like at a dose-selection decision.

2. Are we ready to submit?

“Ready” means different things for an investigational new drug application (IND) and a marketing application such as an NDA or BLA.

For an IND, the central question is whether the proposed investigation is adequately supported and can proceed with appropriate safeguards for participants. For an NDA or BLA, teams must examine both whether the application is sufficiently complete for review and whether its evidence supports the proposed use, dose, population, and labeling. Submission, acceptance for substantive review, and approval are distinct outcomes.

Readiness therefore requires more than collecting finished documents. The clinical, nonclinical, manufacturing, and regulatory parts of the package must tell a coherent, supportable story. That is the question behind IND readiness before first-in-human work and NDA readiness before a filing decision.

3. What must we resolve next?

Not every gap has the same consequence. A formatting correction, an uncertain dose rationale, and an unresolved manufacturing comparability question may all appear on an issue list, but they should not receive equal attention.

The useful question is which uncertainty could change the next study, submission, investment, or transaction, and how long it would take to resolve. This is a prioritization decision that cuts across the other five questions, and it is the same argument we make about readiness being a decision rather than a checklist.

4. Should we fund or reprioritize?

New evidence can change what the next dollar is likely to accomplish. A larger trial, longer follow-up, a new manufacturing investment, a shifting competitive landscape, or a credible path to a differentiated label can materially change a program's case for funding.

Portfolio reviews should connect scientific and regulatory uncertainty to the time and capital needed to address it. An asset may remain promising while becoming the wrong investment for a particular organization at a particular time.

5. Should we acquire, license, or partner?

Diligence should test the assumptions behind the deal, not simply confirm that documents exist. Questions may include how durable the observed effect is, what safety management might require, whether the proposed development timeline is credible, how mature the manufacturing process is, and whether additional studies or comparability work may be needed.

A finding does not always end a transaction. It can change the development plan, risk allocation, milestones, price, or decision to proceed. Absence of evidence deserves the same scrutiny, which we cover in reading a data room for what is missing.

6. When should we pause?

A pause is warranted when the evidence no longer supports the next step, a material uncertainty needs investigation, or the cost of resolving it may exceed the value of continuing. A pause can be temporary. It can also lead to a change in indication, dose, study design, or ownership.

The distinction is between a problem with a feasible path to resolution and a development thesis that has materially weakened. Patient safety concerns may also require immediate action, regardless of the timetable for a portfolio review.

One finding can change several decisions

Consider an illustrative Phase 2 program with encouraging efficacy. During longer follow-up, a hepatic safety signal emerges. The cases observed to date have resolved, but the signal appears more frequently with greater exposure and at the dose the team planned to take forward.

The first task is to evaluate the finding and take any appropriate steps to protect study participants. Its severity, pattern, potential causes, relationship to treatment, and implications for ongoing and future studies need careful assessment. The fact that observed cases resolved does not, by itself, establish that the risk is manageable.

That assessment could change several decisions:

• Advance: Is the planned dose and next study still justified?
• Resolve: What additional analysis or evidence is needed before committing to the next trial?
• Fund: How would a revised dose or study plan affect cost and timing?
• Partner: How does the finding change diligence, deal assumptions, or risk allocation?
• Pause: Should enrollment or further development wait while the signal is investigated?

Make the connection between evidence and action visible

A useful decision record does not need to predict the future. It should make the current reasoning inspectable:

• What new finding or assumption changed?
• Which decisions depend on it?
• What does the evidence support, and what remains uncertain?
• What options are available, who owns the next action, and what would trigger reassessment?

Alenvo's approach to decision intelligence is built around connecting evidence to the decisions it informs. Clinical, nonclinical, CMC, and regulatory information should be usable across development planning, readiness assessments, portfolio reviews, and asset diligence.

Drug assets move forward when the evidence continues to justify the decisions made around them. When the evidence changes, those decisions deserve another look.